FY2025 EPS Estimates for Alumis Decreased by Analyst

Alumis Inc. (NASDAQ:ALMS - Free Report) - Equities researchers at Cantor Fitzgerald dropped their FY2025 earnings estimates for shares of Alumis in a note issued to investors on Tuesday, June 17th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will post earnings per share of ($5.15) for the year, down from their previous estimate of ($3.55). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Alumis' current full-year earnings is ($8.51) per share. Cantor Fitzgerald also issued estimates for Alumis' FY2026 earnings at ($3.28) EPS.

ALMS has been the topic of several other research reports. HC Wainwright reaffirmed a "buy" rating and issued a $14.00 price target on shares of Alumis in a report on Wednesday, April 30th. Guggenheim raised shares of Alumis to a "buy" rating and set a $18.00 price target for the company in a research report on Tuesday, June 10th. Finally, Oppenheimer reduced their price target on shares of Alumis from $26.00 to $25.00 and set an "outperform" rating on the stock in a research report on Thursday, May 15th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $22.86.

Alumis Stock Performance

Shares of ALMS traded down $0.17 on Thursday, reaching $2.85. The stock had a trading volume of 475,819 shares, compared to its average volume of 406,323. The firm has a 50-day moving average of $4.34 and a 200 day moving average of $5.89. Alumis has a twelve month low of $2.84 and a twelve month high of $13.53.

Alumis (NASDAQ:ALMS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($1.82) earnings per share for the quarter, missing analysts' consensus estimates of ($1.47) by ($0.35).

Insider Transactions at Alumis

In related news, Director Srinivas Akkaraju bought 159,920 shares of the firm's stock in a transaction that occurred on Friday, May 2nd. The stock was purchased at an average price of $4.55 per share, for a total transaction of $727,636.00. Following the transaction, the director now directly owns 3,426,418 shares of the company's stock, valued at approximately $15,590,201.90. This represents a 4.90% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Foresite Labs, Llc purchased 20,000 shares of the firm's stock in a transaction on Tuesday, May 6th. The shares were purchased at an average cost of $4.34 per share, with a total value of $86,800.00. Following the completion of the purchase, the insider now owns 4,247,670 shares in the company, valued at $18,434,887.80. This represents a 0.47% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 397,044 shares of company stock worth $1,891,895.

Hedge Funds Weigh In On Alumis

A number of hedge funds and other institutional investors have recently modified their holdings of ALMS. Corebridge Financial Inc. grew its stake in Alumis by 53.0% during the 1st quarter. Corebridge Financial Inc. now owns 10,658 shares of the company's stock valued at $65,000 after acquiring an additional 3,693 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Alumis by 77.1% in the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company's stock valued at $69,000 after acquiring an additional 3,823 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Alumis by 64.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company's stock worth $77,000 after acquiring an additional 4,926 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Alumis by 21.7% in the first quarter. Rhumbline Advisers now owns 16,543 shares of the company's stock worth $102,000 after buying an additional 2,949 shares during the last quarter. Finally, Nuveen LLC acquired a new position in Alumis during the 1st quarter worth $105,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.